Impact of protein energy malnutrition on hospitalized patients with lung cancer: A United States population-based cohort study.

Authors

null

Yajur Arya

Department of Internal Medicine, Jefferson-Einstein Hospital, Philadelphia, PA

Yajur Arya , Arshi Syal , Phuuwadith Wattanachayakul , Elvis Obomanu , Joao Manoel da Silveira Lara , Bruce Adrian Casipit , John Charles Leighton , Claudia M. Dourado

Organizations

Department of Internal Medicine, Jefferson-Einstein Hospital, Philadelphia, PA, Department of Internal Medicine,Jefferson-Einstein Hospital, Philadelphia, PA, Department of Medicine, Albert Einstein Healthcare Network, Philadelphia, PA, Department of Internal Medicine, Philadelphia, PA, Jefferson Einstein Medical Center, Philadelphia, PA, Einstein Medical Center, Philadelphia, PA

Research Funding

No funding sources reported

Background: Lung cancer is the leading cause of cancer related deaths in the United States. Patients with advanced lung cancer tend to have varying degrees of protein energy malnutrition (PEM), due to multiple reasons including cancer related cachexia, sarcopenia, and adverse effect of chemotherapy. However, the impact of PEM on clinical outcomes in this subgroup needs further exploration. Methods: We utilized the 2020 National Inpatient Sample (NIS) Database in conducting this retrospective cohort study. We identified patients with lung cancer and PEM using appropriate ICD-10 diagnostic codes. We stratified patients with lung cancer based on the presence or absence of PEM. A survey multivariable logistic and linear regression analysis was used to calculate adjusted odds ratios (ORs) for the primary and secondary outcomes. A p value of <0.05 was considered statistically significant. The aim of this study was to investigate the impact of PEM on in-hospital mortality, hospital length of stay (LOS), and total hospitalization charge among hospitalized patients with lung cancer. Results: We identified a total of 92425 hospitalized patients with lung cancer, of which 10.53% (9739/92425) had comorbid PEM. The overall in-hospital mortality among patients with lung cancer was 5.79% (5360/92425). Among those with concomitant PEM, the mortality rate was significantly higher at 13.13% (1279/9739, p<0.001). Utilizing a stepwise survey multivariable logistic regression model that adjusted for patient and hospital level confounders, PEM was found to be an independent predictor of increased in-hospital mortality (adjusted OR 2.11; 95% (confidence interval [CI] 1.77-2.51; p<0.001), longer LOS (coefficient 3.02; CI 2.62-3.42; p<0.001), and higher total hospitalization charge (coefficient $22105; CI $13423- $30786; p<0.001). Conclusions: Our analysis demonstrated that PEM was widely prevalent in hospitalized patients with lung cancer and associated with worse outcomes. Efforts should be made to promote nutritional assessment and screening mechanisms with the aim to initiate early nutritional support as indicated. Further prospective studies are warranted to better understand these associations and guide management.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Quality Care/Health Services Research

Track

Care Delivery and Quality Care

Sub Track

Real-World Data/Outcomes

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 11160)

DOI

10.1200/JCO.2024.42.16_suppl.11160

Abstract #

11160

Poster Bd #

355

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Annual Meeting

Cancer in Southeast Asia: A comparative analysis of 2022 incidence and mortality data.

First Author: Edward Christopher Christopher Dee

First Author: Vaishali Deenadayalan

First Author: Catherine Ostos

First Author: Kuldeepsinh Atodaria